




RealRate

PHARMACEUTICAL 2017

Crescent Biopharma INC
Rank 125 of 308

GlycoMimetics, Inc.
Innovation Today, Healing Tomorrow.



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Crescent Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Crescent Biopharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 93% points. The greatest weakness of Crescent Biopharma INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 291%, being 46% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	40,520
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,334
Liabilities, Non-Current	0
Other Assets	812
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	754
Other Net Income	104
Other Revenues	18
Property and Equipment	1,056
Research and Development	23,282
Selling, General and Administrative Expense	8,650

Output Variable	Value in 1000 USD
Assets	42,388
Liabilities	7,087
Expenses	31,932
Revenues	18
Stockholders Equity	35,301
Net Income	-31,810
Comprehensive Net Income	-31,810
BaseVar	40,765
ECR before LimitedLiability	183%
Economic Capital Ratio	291%